West Pharmaceutical Services (NYSE:WST) has expanded its analytical services capabilities with new equipment to help address the pharmaceutical industry’s packaging and drug-delivery concerns, the company said today. West specifically highlighted its addition of an ion mobility quadrupole time-of-flight mass spectrometer – an instrument that combines chromatography, ion mobility and mass spectrometry. The company also added a […]
Here are the pharma companies accused of blocking generic competition
To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]
Cerus lands additional $15m in government funding
Cerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million. The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology. Cerus’ Phase III […]
FDA approves first non-opioid treatment for opioid withdrawal symptoms
The FDA today approved the first non-opioid treatment designed to help manage the symptoms of opioid withdrawal in adults. The drug, Lucemyra, isn’t a treatment for opioid use disorder, the agency noted. Instead, it is meant to be used as part of a broader plan to help adults manage their symptoms when they stop using […]
Bayer wins second approval in China for Eylea eye drug
Bayer (ETR:BAYN) said today that its eye drug, Eyelea, was approved by the Chinese authorities to treat patients with wet age-related macular degeneration. The pharmaceutical giant’s aflibercept injection is already cleared in China to treat visual impairment due to diabetic macular edema. Age-related macular degeneration accounts for 8.7% of all blindness, according to Bayer – that’s […]
Medtronic launches study of drug-eluting stent as treatment for bifurcation lesions
Medtronic (NYSE:MDT) today launched a study to evaluate the safety and efficacy of its Resolute Onyx drug-eluting stent for the treatment of bifurcation lesions in patients with coronary artery disease. The medtech giant said that bifurcation lesions make up nearly 20% of all percutaneous coronary interventions. The assessment of DES tech in this patient group is part […]
HHS secretary calls on drug companies to ‘stop the price hikes’
After President Donald Trump’s drug pricing speech last week was deemed a “non-event” by analysts, all eyes turned to the secretary of the U.S. Dept. of Health & Human Services, Alex Azar, to see what the former pharma executive viewed as the administration’s top concerns. Azar called on the industry to “stop the price hikes” […]
Reva touts first implant of bioresorbable scaffold in Turkey
Reva Medical (ASX:RVA) said today that the company launched its Fantom bioresorbable scaffold in Turkey. There are nearly 100 hospitals performing cardiac catheterizations in Istanbul, according to Reva. The San Diego, Calif.-based company highlighted Turkey as an important market for bioresorbable technologies, noting that it has a commercial distribution deal in the country with Kardionet Healthcare and […]
Aerie seeks FDA nod for Roclatan once-daily eye drop
Aerie Pharmaceuticals (NSDQ:AERI) said today that it submitted a new drug application to the FDA for its once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The company’s Roclatan product is a fixed-dose combination of two drugs – netarsudil and latanoprost. Aerie’s latest eye drug was proven to be safe and […]
PolarityTE aims to ‘wage war on skin grafts’ with regenerative tech
PolarityTE wants to eliminate skin grafts with its platform of regenerative technology. The Utah-based biotech is still new to the industry, but co-founders Denver Lough and Ned Swanson are betting that their company can take on the clinical standard of care for wound management. “No other product, whether it be a drug, a biologic device, […]
